Clinical

An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.

In addition to current available risk scores, the new system can help counsel patients with myelofibrosis (MF) undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT), authors wrote.

Study authors said the findings could inform clinicians when selecting therapies for patients with type 2 diabetes (T2D). However, an editorial found the follow-up period too short and differences between the study arms too small to be meaningful.

Managing itch associated with atopic dermatitis is a critical intervention to patient quality of life.

Medical experts navigate the selection process for optimal atopic dermatitis treatment strategies from provider and payer perspectives.

To address the research gap in familial focal epilepsy with variable foci (FFEVF), investigators assessed the clinical features of a family with FFEVF that included 4 patients in 3 generations and 1 healthy member.

Fecal microbiota transplantation (FMT) has emerged as a highly successful therapeutic strategy for recurrent Clostridioides difficile infection (CDI) in recent years.

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise in treatment of pediatric low-grade glioma.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, discussed the issue of cost and optimizing patient outcomes acute myeloid leukemia (AML).

A recent study found that patients with advanced solid cancers with high tumor mutational burden (TMB) saw improved outcomes on immune checkpoint inhibitors (ICIs) compared with patients who had low-TMB cancers.

A review article investigating the use of bevacizumab biosimilars found that despite lingering concerns about their usage for extrapolated indications, bevacizumab biosimilars are regularly used in metastatic colorectal cancer (mCRC) even though clinical tests only evaluate them in patients with lung cancer.

Researchers set out to examine the effects of sodium nitroprusside on the thromboxane-mediated contraction and nitric oxide (NO)-independent relaxation pathways and on reactive oxygen species accumulation in pulmonary artery smooth muscle cells.

In her closing thoughts, Dr Michos highlights social determinants of health impacting the treatment landscape for patients with cardiovascular disease.

Inclusivity in clinical trials to achieve equitable care.

Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.

Derek van Amerongen, MD, MS, drives a panel discussion surrounding disparities currently faced by women in health care.

Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).

Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.

Chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are type 2 inflammatory conditions that frequently coexist, the with the latter increasing the symptom burden of the former

A panel of multiple myeloma experts discuss costs associated with relapsed/refractory disease.

Treatment considerations for relapsing multiple myeloma is discussed by key opinion leaders.

The partnership will help develop standards for data transfer to eliminate manual steps used in clinical trials.

A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.

These factors could provide a scientific basis for consistency evaluations of the quality and efficacy of insulin biosimilars, study authors wrote.

Gene therapies could have a major impact, although the cost and complexities could inhibit their wide rollout, study authors said.